Compare Apple Inc (AAPL) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Cardinal Health Inc — how do they compare? Apple Inc trades at $304.06 (market cap $4.45T), while Cardinal Health Inc trades at $240 (market cap $55.88B). The key difference: Apple Inc is far larger — about 79.6× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| AAPL | CAH | |
|---|---|---|
Market Cap | $4.45T | $55.88B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $240.26 |
52-Week Low | $224.90 | $146.04 |
Enterprise Value | $4.47T | $59.91B |
Dividend Yield | 0.35% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
